Latest Breaking News On - Biology translational research - Page 1 : comparemela.com
Oncternal Therapeutics Inc (ONCT) Presents New Preclinical Data from its anti-ROR1 Cell Therapy Collaboration with the Karolinska Institutet
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Oncternal Therapeutics Presents New Preclinical Data from its anti-ROR1 Cell Therapy Collaboration with the Karolinska Institutet at the EHA2022 Congress
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
AbbVie to Showcase Breadth of Oncology Portfolio and Pipeline at the 2021 ASCO and EHA Annual Congresses
ABBVie will present results from 43 abstracts across 12 types of cancer during the upcoming virtual American Society of Clinical Oncology Annual Meeting and the virtual European Hematology Association congress . “We are advancing discovery and innovation to improve on the standards of care for blood cancer treatment,” said Mohamed Zaki M.D., Ph.D., vice president and global head of oncology development, AbbVie. “We …
– ABBVie (NYSE: ABBV) will present results from 43 abstracts across 12 types of cancer during the upcoming virtual American Society of Clinical Oncology (ASCO) Annual Meeting ( June 4-8 ) and the virtual European Hematology Association (EHA) congress ( June 9-17 ).
Share this article
Share this article
LEXINGTON, Mass., May 12, 2021 /PRNewswire/ Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that two abstracts for CA-4948, a novel, small molecule IRAK4 inhibitor, have been accepted for oral and poster presentation at the European Hematology Association 2021 Virtual Congress (EHA), which will be held virtually from June 9-17, 2021. The abstracts include updated data from a February data-cut for its ongoing open-label, single arm, Phase 1/2 study of CA-4948 in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS). We are very pleased to report this clinical update on our first-in-class IRAK4 kinase inhibitor, CA-4948, as an anticancer agent for patients with acute myeloid leukemia and myelodysplastic syndromes for whom multiple prior lines of therapy have been unsuccessful, said James Dentzer, Presiden
Immunicum AB: Immunicum Announces Presentations at the European Hematology Association (EHA) 2021 Virtual Congress
Immunicum AB
. The presentations include interim immunological results from the Phase II ADVANCE II study, demonstrating DCP-001 s ability to induce immune responses to a broad range of tumor-associated antigens in acute myeloid leukemia (AML) patients, as well as preclinical results of enhanced efficacy when combining DCP-001 with established AML treatment regimens. From the interim clinical data published in the abstract today, we are excited to see that DCP-001 induces a range of detectable immune responses in AML patients participating in our ongoing ADVANCE II study, said
vimarsana © 2020. All Rights Reserved.